The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback